These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31153654)

  • 1. Efficacy and safety of combined neprilysin and RAS inhibition in heart failure: A meta-analysis of randomized controlled trials.
    Geng Q; Li S; Wang Z; Ren Y
    Int J Cardiol; 2019 Oct; 293():159-164. PubMed ID: 31153654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis.
    Solomon SD; Claggett B; McMurray JJ; Hernandez AF; Fonarow GC
    Eur J Heart Fail; 2016 Oct; 18(10):1238-1243. PubMed ID: 27364182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials.
    Feng Y; Yin Y; Deng R; Li H
    J Clin Pharm Ther; 2020 Dec; 45(6):1235-1243. PubMed ID: 32776562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.
    Xie W; Zheng F; Song X; Zhong B; Yan L
    Int J Cardiol; 2016 Feb; 205():65-71. PubMed ID: 26720043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher versus lower doses of ACE inhibitors, angiotensin-2 receptor blockers and beta-blockers in heart failure with reduced ejection fraction: Systematic review and meta-analysis.
    Turgeon RD; Kolber MR; Loewen P; Ellis U; McCormack JP
    PLoS One; 2019; 14(2):e0212907. PubMed ID: 30817783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
    Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
    Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.
    Makani H; Bangalore S; Desouza KA; Shah A; Messerli FH
    BMJ; 2013 Jan; 346():f360. PubMed ID: 23358488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety profile of angiotensin receptor neprilysin inhibitors in the management of heart failure: a systematic review and meta-analysis of randomized controlled trials.
    Gao J; Zhao C; Zhang WZ; Liu S; Xin H; Lian ZX
    Heart Fail Rev; 2023 Jul; 28(4):905-923. PubMed ID: 36184714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line renin-angiotensin system inhibitors vs. other first-line antihypertensive drug classes in hypertensive patients with type 2 diabetes mellitus.
    Wang G; Chen Y; Li L; Tang W; Wright JM
    J Hum Hypertens; 2018 Jul; 32(7):494-506. PubMed ID: 29713053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on cardiovascular events in patients with heart failure: a meta-analysis of randomized controlled trials.
    Tai C; Gan T; Zou L; Sun Y; Zhang Y; Chen W; Li J; Zhang J; Xu Y; Lu H; Xu D
    BMC Cardiovasc Disord; 2017 Oct; 17(1):257. PubMed ID: 28982370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockers for hypertension.
    Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.
    Fukuta H; Goto T; Wakami K; Ohte N
    Heart Fail Rev; 2017 Nov; 22(6):775-782. PubMed ID: 28702858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure: a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis.
    Nielsen EE; Feinberg J; Raymond I; Olsen MH; Steensgaard-Hansen FV; Jakobsen JC
    Syst Rev; 2019 Oct; 8(1):251. PubMed ID: 31672170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of renin-angiotensin system inhibitors on mortality, cardiovascular events, and renal events in hypertensive patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
    Kunimura A; Himuro N; Fujiyoshi A; Segawa H; Ohnishi H; Saitoh S
    Hypertens Res; 2019 May; 42(5):669-680. PubMed ID: 30948835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Test in Context: Neprilysin: Function, Inhibition, and Biomarker.
    Bayes-Genis A; Barallat J; Richards AM
    J Am Coll Cardiol; 2016 Aug; 68(6):639-653. PubMed ID: 27491909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.